PubMed: 36216945 SEMALEAN Study , Berriche O, et al
6 Dulaglutide (Trulicity): Mainly marketed as Trulicity in the US, dulaglutide has had FDA approval for type 2 diabetes management since 2014
They also show promise for the treatment of many inflammatory diseases including asthma and inflammatory bowel disorders like Crohns disease and ulcerative colitis Diagram showing food stimulating the release of GLP-1 into the intestine and its effects on the brain, stomach and pancreas Importance In 2023 GLP-1 based drugs was named breakthrough of the year by Science , a prestigious American journal
Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide or tirzepatide
Nutritional optimisation is fundamental
[14] Michaels recently formed a partnership with Bill Maher's Club Random to expand her audio podcast "Keeping It Real" to video